Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade C 15.84 -0.94% -0.15
IMMU closed down 0.94 percent on Thursday, January 18, 2018, on 46 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
8 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical IMMU trend table...

Date Alert Name Type % Chg
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 1,2,3 Pullback Bullish Bullish Swing Setup -0.94%
Jan 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.94%
Jan 17 Wide Bands Range Expansion -0.94%
Jan 16 MACD Bearish Signal Line Cross Bearish 2.39%
Jan 16 1,2,3 Pullback Bullish Bullish Swing Setup 2.39%
Jan 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.39%
Jan 16 Outside Day Range Expansion 2.39%
Jan 16 Wide Bands Range Expansion 2.39%

Older signals for IMMU ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.24
52 Week Low 4.08
Average Volume 3,563,662
200-Day Moving Average 10.0002
50-Day Moving Average 12.9343
20-Day Moving Average 15.572
10-Day Moving Average 16.067
Average True Range 0.9103
ADX 35.18
+DI 25.51
-DI 15.93
Chandelier Exit (Long, 3 ATRs ) 14.5091
Chandelier Exit (Short, 3 ATRs ) 14.7909
Upper Bollinger Band 17.4639
Lower Bollinger Band 13.6801
Percent B (%b) 0.57
BandWidth 24.298741
MACD Line 0.9335
MACD Signal Line 1.0825
MACD Histogram -0.1491
Fundamentals Value
Market Cap 1.76 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.78
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.71
Resistance 3 (R3) 16.75 16.50 16.57
Resistance 2 (R2) 16.50 16.28 16.48 16.52
Resistance 1 (R1) 16.17 16.14 16.05 16.13 16.47
Pivot Point 15.92 15.92 15.86 15.90 15.92
Support 1 (S1) 15.59 15.70 15.47 15.55 15.21
Support 2 (S2) 15.34 15.56 15.32 15.16
Support 3 (S3) 15.01 15.34 15.12
Support 4 (S4) 14.97